SCHEMBL7996487

SCHEMBL7996487

COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3ccco3)CC2)C1=O

nearest known ligand 0.68

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
OPRL1 P41146 10/20 0.68
MEN1 O00255 2/20 0.68
KMT2A Q03164 2/20 0.68
CYP3A4 P08684 1/20 0.68
CYP2D6 P10635 1/20 0.68
CYP2C9 P11712 1/20 0.68
OPRM1 P35372 10/20 0.59
OPRK1 P41145 8/20 0.59
BDKRB2 P30411 1/20 0.53
OPRD1 P41143 9/20 0.52
DRD2 P14416 3/20 0.52
DRD3 P35462 3/20 0.52
NPC1L1 Q9UHC9 3/20 0.50
DRD4 P21917 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7994093 0.87 OPRL1 (0.66) OPRL1MEN1KMT2ACYP3A4CYP2D6
SCHEMBL7994088 0.87 OPRL1 (0.66) OPRL1MEN1KMT2ACYP3A4CYP2D6
SCHEMBL7995959 0.84 MEN1 (0.71) OPRL1MEN1KMT2ACYP3A4CYP2D6
SCHEMBL7992822 0.83 OPRL1 (0.77) OPRL1MEN1KMT2ACYP3A4CYP2D6
SCHEMBL7759170 0.83 MEN1 (0.77) OPRL1MEN1KMT2ACYP3A4CYP2D6
SCHEMBL7992852 0.83 OPRL1 (0.77) OPRL1MEN1KMT2ACYP3A4CYP2D6
SCHEMBL7995842 0.83 CYP2D6 (0.80) OPRL1MEN1KMT2ACYP3A4CYP2D6
SCHEMBL7982553 0.82 OPRL1 (0.78) OPRL1MEN1KMT2ACYP3A4CYP2D6
SCHEMBL20187031 0.81 OPRL1 (0.67) OPRL1MEN1KMT2ACYP3A4CYP2D6
SCHEMBL7992816 0.81 OPRL1 (0.66) OPRL1MEN1KMT2ACYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6277991-B1 FOR TREATMENT OF MIGRAINE, NON-INSULIN DEPENDENT DIABETES MELLITUS, SEPSIS, INFLAMMATION, INCONTINENCE, VASOMOTOR DISTURBANCES SUCH AS HOT FLUSHES OR HOT FLASHES NOVO NORDISK A/S (DK) 2001-08-21 US disclosed